Figure 3From: Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markersInflammation markers measured by in blood samples collected during treatment with either glimepiride or repaglinide. (A) PAI-1, (B) IL-6, and (C) hs-CRP levels are shown (n = 9). *p < 0.001; **p < 0.05.Back to article page